Consolidated Balance Sheets - USD ($)	Mar. 31, 2020	Jun. 30, 2019
CURRENT ASSETS
Cash	$ 11,568	$ 27,453
Prepaid expenses and other assets	13,968	9,470
Tax refunds receivable	12,568	6,852
Accounts receivable, net	11,344	29,525
Note receivable, related party	3,428	5,671
Total Current Assets	52,876	78,971
Operating lease right-of-use asset	73,365	0
TOTAL ASSETS	126,241	78,971
LIABILITIES
Accounts payable and accrued expenses	114,843	164,145
Accrued interest - related party	37,577	28,458
Notes payable - related party	565,167	478,357
Operating lease liability -short term	8,381	0
Total Current Liabilities	725,968	670,960
Operating lease liability -long term	64,984	0
Total Liabilities	790,952	670,960
STOCKHOLDERS' DEFICIT
Preferred stock, no par value; 10,000,000 shares authorized, -0- shares issued and outstanding	0	0
Common stock, no par value; 250,000,000 shares authorized 202,783,598 and 199,295,503 shares issued and 202,729,842 and 199,241,747 shares outstanding respectively	33,023,316	32,967,499
Additional paid-in capital	4,513,328	4,513,328
Treasury stock, at cost	(19,387)	(19,387)
Accumulated other comprehensive income	90,318	91,447
Accumulated deficit	(37,627,112)	(37,503,684)
Total Sangui Biotech International, Inc's stockholders' equity (defict)	(19,537)	49,203
Non-controlling interest	(645,174)	(641,192)
Total Stockholders' Deficit	(664,711)	(591,989)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	$ 126,241	$ 78,971